Division of Biostatistics, Department of Population Health and Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, United States
Research Article
A Phase I Study of Immune Checkpoint Inhibition (anti-
CTLA4 and anti-PD-L1) in Combination with Radiation
Therapy in Patients with Locally Advanced Unresectable
Pancreatic Cancer
Author(s): Jennifer Wu*, Emily C Atkinson, Kevin Du, Susanna Nguy, Anna C Pavlick, Judith D Goldberg, Daniel Becker, Elaine Shum, Steve Y Lee, George Miller, Jennifer Chuy and Lawrence Leichman
Background: No clear consensus exists on the best treatment for unresectable locally advanced pancreatic cancer. Programmed death ligand-1 (PD-L1) inhibitors and
cytotoxic T lymphocyte antigen-4 (CTLA-4) inhibitors, especially in combination, have been shown to increase survival in a variety of cancers. Preclinical data indicates
potential synergy between immunotherapy, such as PD-L1 and CTLA-4 inhibitors, with radiation therapy. Specifically, in combination with Stereotactic Body Radiation
Therapy (SBRT), immunotherapy may provide an effective treatment modality for this difficult-to-treat patient population.
Aim: To determine the safety and recommended phase 2 dose (RP2D) of SBRT in combination with either (A) Durvalumab (MEDI4736) alone, (B) Tremelimumab alone or
(C) the combination of Durvalumab (MEDI4736) and Tremelimumab for .. Read More»
DOI:
10.37421/cgj.2020.5.125
Clinical Gastroenterology Journal received 33 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 